Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
Exp. Mol. Med., 08 January 2025 | https://doi.org/10.1038/s12276-024-01382-0
Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond to neoadjuvant treatment: A retrospective cohort study
Int. J. Surg., Sep 23 2024, | https://doi.org/10.1097/JS9.0000000000002034
Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: A retrospective cohort study
Int. J. Surg., Feb 19 2024, | https://doi.org/10.1097/JS9.0000000000001184
Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study
Clin. Chem., 2022 Dec 6;68(12):1509-1518 | https://doi.org/10.1093/clinchem/hvac153
A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
Clin. Cancer Res., Published first February 16, 2021 | DOI: 10.1158/1078-0432.CCR-20-3513